Coming Soon

Expanding our portfolio to support emerging CAR T cell therapies

Products in Development

We are actively developing detection reagents for additional CAR T cell targets to meet the evolving needs of cell therapy monitoring.

CD33 Detection Reagent

COMING SOON

Detection reagent for CD33-targeting CAR T cells, designed for acute myeloid leukemia (AML) therapeutic monitoring applications.

Target: CD33
Indication: AML

CD20 Detection Reagent

COMING SOON

Optimized reagent for CD20-directed CAR T cells, supporting monitoring workflows in B-cell lymphoma treatments.

Target: CD20
Indication: B-cell Lymphoma

GPRC5D Detection Reagent

COMING SOON

Novel detection reagent for GPRC5D-targeting CAR T cells, addressing emerging multiple myeloma treatment modalities.

Target: GPRC5D
Indication: Multiple Myeloma

Join Our Early Access Program

Be among the first to evaluate these new detection reagents. Early access participants receive:

  • Priority access to products as they become available
  • Introductory pricing and evaluation samples
  • Opportunity to provide feedback during product development
  • Direct technical support from our development team

Need a Different Target?

We are open to discussing custom development projects for additional CAR targets. If you have specific monitoring needs not addressed by our current or planned portfolio, we'd like to hear from you.